RxDoctor Payments Data

Alan Soroka, MD

Internal Medicine · Windsor Locks, CTNPI 1720065428

Payments from drug & device makers

$15,191in general payments, 2019–2025

Across 660 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$1K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$966
  • Boehringer Ingelheim$794
  • Bayer$755
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$15,07599%
  • Education$1161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,191 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$50,095
Medicare patients
82
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol108$113,254
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$89,869
JanuviaSitagliptin Phosphate56$71,931
MounjaroTirzepatide50$69,084
JardianceEmpagliflozin68$67,304
XareltoRivaroxaban56$57,180
EliquisApixaban38$42,520
EntrestoSacubitril/Valsartan32$28,414
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$27,850
Breo ElliptaFluticasone/Vilanterol30$16,412
KerendiaFinerenone11$15,588
Nurtec OdtRimegepant Sulfate14$14,400
TrulicityDulaglutide13$13,023
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$12,933
Oxycodone Hcl288$4,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,774$143,971161 claims
GSKTrelegy Ellipta, Breo Ellipta$1,264$106,281137 claims
Lilly USA, LLCMounjaro, Trulicity$966$82,10763 claims
MerckJanuvia$160$71,93156 claims
Boehringer IngelheimJardiance$794$67,30468 claims
Johnson & JohnsonXarelto$1,164$57,18056 claims
PfizerEliquis, Nurtec Odt$743$56,92052 claims
NovartisEntresto$560$28,41432 claims
BayerKerendia$755$15,58811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Windsor Locks

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →